You are here
One of the primary challenges in effectively treating brain cancers is the ability to get therapeutic agents into the brain; the blood-brain barrier (BBB) acts as a natural defense system to keep most drugs out. Angiochem addresses this challenge by engineering its drugs with the dual-targeting ability of crossing the BBB via the lipoprotein receptor-related protein (LRP-1) as well as to access cancer cells expressing LRP-1 throughout the body and in the brain.
In the area of oncology, Angiochem has multiple pharmacologic agents designed to cross the blood-brain barrier under evaluation, including ANG1005, currently in clinical development. > More about ANG1005
Angiochem has created a brain penetrant peptide-antibody conjugate of anti-Her2 (ANG4043) that penetrates the brain in therapeutic concentrations. > More about ANG4043